Is There a Difference between Levodopa/ Dopa-Decarboxylase Inhibitor and Entacapone and Levodopa/Dopa-Decarboxylase Inhibitor Dose Fractionation Strategies in Parkinson’s Disease Patients Experiencing Symptom Re-Emergence due to Wearing-Off?

Publisher： Karger

E-ISSN： 1421-9913|61|2|69-75

ISSN： 0014-3022

Source： European Neurology, Vol.61, Iss.2, 2008-11, pp. : 69-75

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo® (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess®/Comtan® (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment

By  

European Neurology, Vol. 53, Iss. 4, 2005-07 ,pp. : 197-202

Karger

Access to resources Recommend Favorite

Efficacy and Tolerability of Entacapone as Adjunctive Therapy to Levodopa in Patients with Parkinson’s Disease and End-of-Dose Deterioration in Daily Medical Practice: An Open, Multicenter Study

By  

European Neurology, Vol. 45, Iss. 2, 2001-02 ,pp. : 111-118

Karger

Access to resources Recommend Favorite

The Influence of Levodopa and the COMT Inhibitor on Serum Vitamin B12 and Folate Levels in Parkinson’s Disease Patients

By  

European Neurology, Vol. 58, Iss. 2, 2007-06 ,pp. : 96-99

Karger

Access to resources Recommend Favorite

When Do Levodopa Motor Fluctuations First Appear in Parkinson’s Disease?

By  

European Neurology, Vol. 63, Iss. 5, 2010-03 ,pp. : 257-266

Karger

Access to resources Recommend Favorite

Switch-Over from Tolcapone to Entacapone in Severe Parkinson’s Disease Patients

By  

European Neurology, Vol. 46, Iss. 1, 2001-07 ,pp. : 11-16

Karger

Access to resources Recommend Favorite